State-of-the-art treatment and novel agents in chronic lymphocytic leukemia

Oncology Research and Treatment

Volumn 39, Issue 1-2, 2016, Pages 25-32

  Cramer, Paula ^a   Hallek, Michael ^a,b   Eichhorst, Barbara ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chronic lymphocytic leukaemia; Relapse, refractory; Treatment, first line

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; IDELALISIB; RITUXIMAB; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

CANCER GROWTH; CANCER RISK; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; HUMAN; LEUKEMIA RELAPSE; REVIEW; TREATMENT OUTCOME; EVIDENCE BASED MEDICINE; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84959224524     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000443903     Document Type: Review

References (86)

1. Morton LM, Wang SS, Devesa SS, et al.: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-276.
2. Watson L, Wyld P, Catovsky D: Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol 2008; 81: 253-258.
3. Molica S: Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 2006; 47: 1477-1480.
4. Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 Guidelines. Blood 2008; 111: 5446-5456.
5. Mauro FR, Foa R, Giannarelli D, et al.: Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases. Blood 1999; 94: 448-454.
6. Rawstron AC, Bennett FL, O'Connor SJ, et al.: Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359: 575-583.
7. Döhner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. New Engl J Med 2000; 343: 1910-1916.
8. Malcikova J, Smardova J, Rocnova L, et al.: Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: Selection, impact on survival, and response to DNA damage. Blood 2009; 114: 5307-5314.
9. Zenz T, Benner A, Dohner H, Stilgenbauer S: Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. Cell cycle 2008; 7: 3810-3814.
10. Oscier D, Fitchett M, Herbert T, Lambert R: Karyotypic evolution in B-cell chronic lymphocytic leukaemia. Genes Chromosomes Cancer 1991; 3: 16-20.
11. Malcikova J, Stano-Kozubik K, Tichy B, et al.: Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia 2015; 29: 877-885.
12. Landau DA, Carter SL, Stojanov P, et al.: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
13. Puente XS, Lopez-Otin C: The evolutionary biography of chronic lymphocytic leukemia. Nat Genet 2013; 45: 229-231.
14. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 2000; 5: 224-237.
15. Eichhorst B, Goede V, Hallek M: Treatment of elderly patients with chronic lymphocytic leukemia. Leuk lymphoma 2009; 50: 171-178.
16. Goede V, Hallek M: Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: Considerations in the elderly. Drugs Aging 2011; 28: 163-176.
17. Gribben JG: One step back but 2 steps forward. Blood 2009; 114: 3359-3360.
18. Linn BS, Linn MW, Gurel L: Cumulative illness rating scale. J Am Geriatr Soc 1968; 16: 622-626.
19. Eichhorst BF, Busch R, Stilgenbauer S, et al.: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382-3391.
20. Han T, Ezdinli EZ, Shimaoka K, Desai DV: Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973; 31: 502-508.
21. Knospe WH, Loeb V Jr: Biweekly chlorambucil treatment of lymphocytic lymphoma. Cancer Clin Trials 1980; 3: 329-336.
22. Eichhorst BF, Busch R, Hopfinger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
23. Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007; 370: 230-239.
24. Flinn IW, Neuberg DS, Grever MR, et al.: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793-798.
25. Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
26. Goede V, Fischer K, Busch R, et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110.
27. Goede V, Fischer K, Engelke A, et al.: Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study. Leukemia 2015; 29: 1602-1604.
28. O'Brien S, Jones JA, Coutre S, et al.: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: Results from the phase II RESONATETM-17 trial. ASH Annual Meeting Abstracts 2014.
29. Sharman JP, Coutre SE, Furman RR, et al.: Second interim analysis of a phase 3 study of idelalisib (zydelig) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. ASH Annual Meeting Abstracts 2014.
30. Souers AJ, Leverson JD, Boghaert ER, et al.: Abt-199, a potent and selective bcl-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
31. Roberts AW, Ma S, Brander DM, et al.: Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed / refractory (R/R) chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2014.
32. Tam CS, O'Brien S, Plunkett W, et al.: Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 2014; 124: 3059-3064.
33. Fischer K, Bahlo J, Fink AM, et al.: Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the cll8 trial. Blood 2015 [Epub ahead of print].
34. Bosch F, Abrisqueta P, Villamor N, et al.: Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4578-4584.
35. Faderl S, Wierda W, O'Brien S, et al.: Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCMR) in frontline CLL <70 years. Leuk Res 2010; 34: 284-288.
36. Brown JR, Abramson J, Hochberg E, et al.: A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010; 24: 1972-1975.
37. Mato AR, Foon KA, Feldman T, et al.: Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCRLite) plus lenalidomide, followed by lenalidomide consolidation/ maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol 2015; 90: 487-492.
38. Parikh SA, Keating MJ, O'Brien S, et al.: Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011; 118: 2062-2068.
39. Geisler CH, van T' Veer MB, Jurlander J, et al.: Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood 2014; 123: 3255-3262.
40. Lepretre S, Aurran T, Mahe B, et al.: Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 2012; 119: 5104-5110.
41. Foon KA, Boyiadzis M, Land SR, et al.: Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 498-503.
42. Foon KA, Mehta D, Lentzsch S, et al.: Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 2012; 119: 3184-3185.
43. Kay NE, Geyer SM, Call TG, et al.: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated b chronic lymphocytic leukemia. Blood 2007; 109: 405-411.
44. Reynolds C, Di Bella N, Lyons RM, et al.: A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. Pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs 2012; 30: 1232-1240.
45. Robak T, Smolewski P, Cebula B, et al.: Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007; 79: 107-113.
46. Kay NE, Wu W, Kabat B, et al.: Pentostatin and rituximab therapy for previously untreated patients with Bcell chronic lymphocytic leukemia. Cancer 2010; 116: 2180-2187.
47. Fischer K, Cramer P, Busch R, et al.: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29: 3559-3566.
48. Fischer K, Cramer P, Busch R, et al.: Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30: 3209-3216.
49. Eichhorst B, Fink A-M, Busch R, et al.: Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study). ASH Annual Meeting Abstracts 2014.
50. Wierda WG, Kipps TJ, Durig J, et al.: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 117: 6450-6458.
51. Shanafelt T, Lanasa MC, Call TG, et al.: Ofatumumabbased chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer 2013; 119: 3788-3796.
52. Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
53. Hillmen P, Skotnicki AB, Robak T, et al.: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
54. Knauf WU, Lissichkov T, Aldaoud A, et al.: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-4384.
55. Eichhorst BF, Bahlo J, Busch R, et al.: Long-term follow-up of a randomized phase III comparing fludarabine and chlorambucil in first line therapy of elderly patients with advanced chronic lymphocytic leukemia. ICML Meeting Abstracts, Lugano 2013.
56. Herter S, Herting F, Mundigl O, et al.: Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013; 12: 2031-2042.
57. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al.: Binding of submaximal C1q promotes complementdependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009; 183: 749-758.
58. Hillmen P, Robak T, Janssens A, et al.: Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): Results of the phase III study complement 1 (OMB110911). ASH Annual Meeting Abstracts 2013; 122:abstr 528.
59. Offner F, Panagiotidis P, Afanasyev B, et al.: Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: Initial results of the phase II study OMB115991. XV IWCLL Meeting Abstracts 2013: 429.
60. Ujjani C, Ramzi P, Gehan E, et al.: Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk lymphoma 2015; 56: 915-920.
61. Dartigeas C, Van den Neste E, Berthou C, et al.: Safety and efficacy of abbreviated induction with oral fludarabine (F) and cyclophosphamide (C) combined with dose-dense IV rituximab (R) in previously untreated patients with chronic lymphocytic leukemia (CLL) aged > 65 years : Results of a multicenter trial (LLC 2007 SA) on behalf of the French Goelams/fcgcll-WM Intergroup. Blood 2012; 120: 434.
62. Mulligan SP, Gill D, Turner P, et al.: A randomised dose de-escalation study of oral fludarabine, ± oral cyclophosphamide and intravenous rituximab as firstline therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged 65 years: Final analysis of response and toxicity. Blood 2014; 124: 3325.
63. Smolej L, Brychtova Y, Doubek,M, et al.: Low-dose FCR is a safe and effective treatment option for elderly/ comorbid patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma. Updated results of project Q-Lite by Czech CLL Study Group. Blood 2014; 124: 4670.
64. Stilgenbauer S, Sander S, Bullinger L, et al.: Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-1245.
65. Osterborg A, Foa R, Bezares RF, et al.: Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 2009; 23: 1980-1988.
66. Hoellenriegel J, Meadows SA, Sivina M, et al.: The phosphoinositide 3-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
67. Herman SE, Gordon AL, Hertlein E, et al.: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-6296.
68. Byrd JC, Brown JR, O'Brien S, et al.: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.
69. Furman RR, Sharman JP, Coutre SE, et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
70. Jones JA, Wach M, Robak T, et al.: Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL). ASCO 2015 Meeting Abstracts. J Clin Oncol 2015; 33:abstr 7023.
71. Dreger P, Corradini P, Kimby E, et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 2007; 21: 12-17.
72. Dreger P, Schetelig J, Andersen N, et al.: Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: Stem cell transplantation or novel agents? Blood 2014; 124: 3841-3849.
73. Eketorp Sylvan S, Hansson L, Karlsson C, et al.: Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: A population-based study from a well-defined geographic region. Leuk Lymphoma 2014; 55: 1774-1780.
74. Cramer P, Isfort S, Bahlo J, et al.: Outcome of advanced chronic lymphocytic leukemia following different firstline-and relapse-therapies: A metaanalysis of five prospective trials of the German CLL Study Group (GCLLSG). Haematologica 2015; 100: 1451-1459.
75. Stilgenbauer S, Zenz T, Winkler D, et al.: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994-4001.
76. Pettitt AR, Jackson R, Carruthers S, et al.: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53:Final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012; 30: 1647-1655.
77. Byrd JC, Furman RR, Coutre SE, et al.: Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497-2506.
78. Byrd JC, Brown JR, O'Brien S, et al.: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.
79. Chanan-Khan AAA, Cramer P, Demirkan F, et al.: Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. ASCO 2015 Meeting Abstracts. J Clin Oncol 2015; 33:abstr LBA7005.
80. Eichhorst B, Dreyling M, Robak T, et al.: Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(Suppl 6):vi50-54.
81. Robak T, Dmoszynska A, Solal-Celigny P, et al.: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1756-1765.
82. Goede V, Engelke A, Fischer K, et al.: Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: Results of the CLL11 study. ASH Annual Meeting Abstracts 2014.
83. Fraser G, Chanan-Khan A, Cramer P, et al.: Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Subgroup efficacy analyses from the HELIOS trial. IWCLL Meeting Abstracts 2015.
84. Hallek M: Signaling the end of chronic lymphocytic leukemia: New frontline treatment strategies. Blood 2013; 122: 3723-3734.
85. Langerbeins P, Groß-Ophoff-Müller C, Herling CD: Risk-adapted therapy in early-stage chronic lymphocytic leukemia. Oncol Res Treat 2016;39: DOI: 10.1159/ 000443013.
86. Tausch E, Mertens D, Stilgenbauer S: Genomic features: impact on pathogenesis and treatment of chronic lymphocytic leukemia. Oncol Res Treat 2016;39: DOI: 10.1159/000443906.